VISTA-16 Trial: Evaluation of the Safety and Efficacy of Short-Term A-002 Treatment in Subjects With Acute Coronary Syndromes.

Trial Profile

VISTA-16 Trial: Evaluation of the Safety and Efficacy of Short-Term A-002 Treatment in Subjects With Acute Coronary Syndromes.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Varespladib (Primary) ; Atorvastatin
  • Indications Acute coronary syndromes; Angina pectoris; Myocardial infarction
  • Focus Registrational; Therapeutic Use
  • Acronyms VISTA-16
  • Sponsors Anthera Pharmaceuticals
  • Most Recent Events

    • 18 Nov 2013 Interim results published in JAMA: the Journal of the American Medical Association.
    • 11 Apr 2012 New source identified and integrated (Clinical Trials Registry - India: CTRI2011-05-001713)
    • 28 Mar 2012 Planned number of patients changed from 6500 to 6504 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top